相关临床试验
7
1 进行中
药物批准
6
批准总数
监管机构
1
监管机构数
成立时间
2004
进行中（未招募）
1
14.3%
已完成
4
57.1%
招募中
1
14.3%
终止
1
14.3%
- Kahn Swick & Foti, LLC has filed a class action securities lawsuit against ADMA Biologics on behalf of investors who purchased shares between August 9, 2024 and March 25, 2026. - The complaint alleges the company failed to disclose a related-party transaction, engaged in channel stuffing to inflate revenue, and lacked adequate internal controls. - The case, Mazzarino v. ADMA Biologics, Inc., is pending in the U.S. District Court for the District of New Jersey under docket number 26-cv-04793. - Affected investors have until August 10, 2026 to apply for lead plaintiff status through KSF Managing Partner Lewis Kahn.
- The FDA has approved ADMA Biologics' supplemental application to expand ASCENIV's indication to include pediatric patients aged 2 years and older with primary humoral immunodeficiency, lowering the previous age restriction from 12 years. - The approval represents completion of the required pediatric assessment post-marketing commitment and allows earlier treatment intervention for younger immune-compromised patients. - ASCENIV is a plasma-derived intravenous immune globulin manufactured using ADMA's patented donor screening methodology and tailored plasma pooling design that includes respiratory syncytial virus plasma. - The expanded indication addresses an important unmet medical need by providing an FDA-approved treatment option for younger pediatric patients with primary immune deficiency disorders.
- ADMA Biologics has received FDA clearance for a yield enhancement process that is expected to significantly improve production margins for its immunoglobulin products starting in 2026. - The company plans to strategically allocate its strong cash flow toward debt reduction, commercial initiatives, R&D support, and potential stock repurchases while maintaining financial flexibility. - Health economic outcome data for ASCENIV is on track for publication later this year, aiming to demonstrate real-world benefits including reduced hospitalizations that justify its premium pricing to payers.
- ADMA Biologics has received FDA approval for a groundbreaking production process that increases immune globulin yields by approximately 20% from the same plasma volume, becoming the first U.S. company to achieve this regulatory milestone. - The yield enhancement technology will benefit both ASCENIV and BIVIGAM product lines, substantially increasing production capacity and supporting revenue growth beginning in late 2025 with further acceleration expected through 2026. - This innovation represents a significant advancement in plasma fractionation efficiency, potentially expanding access to immune globulin treatments for immunocompromised patients while improving the company's profit margins.
